ECSP055849A - Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico - Google Patents

Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Info

Publication number
ECSP055849A
ECSP055849A EC2005005849A ECSP055849A ECSP055849A EC SP055849 A ECSP055849 A EC SP055849A EC 2005005849 A EC2005005849 A EC 2005005849A EC SP055849 A ECSP055849 A EC SP055849A EC SP055849 A ECSP055849 A EC SP055849A
Authority
EC
Ecuador
Prior art keywords
human
binding molecule
nogo
antibody
pharmaceutical use
Prior art date
Application number
EC2005005849A
Other languages
English (en)
Inventor
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schenell
Martin E Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of ECSP055849A publication Critical patent/ECSP055849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a moléculas, tales como, por ejemplo, anticuerpos monoclonales o fragmentos Fab de los mismos, los cuales son capaces de enlazarse con el polipéptido NogoA humano, o NiG humano, o NiG-D20 humano, o NogoA_623-640 humano, con una constante de disociación < 1000 nM; polinucleótidos que codifican esta molécula de enlace; un vector de expresión que comprende estos polinucleótidos; el uso de esta molécula de enlace en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de enlace; y a un método de tratamiento de enfermedades asociadas con la reparación de nervios.
EC2005005849A 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico ECSP055849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound

Publications (1)

Publication Number Publication Date
ECSP055849A true ECSP055849A (es) 2005-09-20

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005849A ECSP055849A (es) 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Country Status (24)

Country Link
US (2) US7785593B2 (es)
EP (1) EP1572745B1 (es)
JP (1) JP4504200B2 (es)
KR (1) KR101215801B1 (es)
CN (1) CN100384877C (es)
AT (1) ATE475671T1 (es)
AU (1) AU2003289998B2 (es)
BR (1) BR0317161A (es)
CA (1) CA2509068C (es)
CY (1) CY1110848T1 (es)
DE (1) DE60333585D1 (es)
DK (1) DK1572745T3 (es)
EC (1) ECSP055849A (es)
ES (1) ES2349293T3 (es)
GB (1) GB0228832D0 (es)
IL (1) IL169018A (es)
MX (1) MXPA05006265A (es)
NO (1) NO20053304L (es)
PL (1) PL210720B1 (es)
PT (1) PT1572745E (es)
RU (1) RU2350623C2 (es)
SI (1) SI1572745T1 (es)
WO (1) WO2004052932A2 (es)
ZA (1) ZA200504522B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (es) 2012-07-05 2015-05-08 Glaxo Group Ltd
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
JP6604942B2 (ja) * 2013-06-13 2019-11-13 バイオマトリカ，インク． 細胞安定化
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
EP4041392A1 (en) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021079002A2 (en) * 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
WO2000031235A2 (en) 1998-11-06 2000-06-02 Schwab Martin E Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
ES2318006T3 (es) * 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
AU2002357770B2 (en) * 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
KR20050095768A (ko) 2005-09-30
PL210720B1 (pl) 2012-02-29
CY1110848T1 (el) 2015-06-10
US20060183678A1 (en) 2006-08-17
EP1572745B1 (en) 2010-07-28
HK1084676A1 (en) 2006-08-04
AU2003289998B2 (en) 2008-02-14
CN1747971A (zh) 2006-03-15
WO2004052932A3 (en) 2004-10-21
NO20053304D0 (no) 2005-07-06
US7785593B2 (en) 2010-08-31
IL169018A (en) 2012-07-31
EP1572745A2 (en) 2005-09-14
US20110059110A1 (en) 2011-03-10
JP4504200B2 (ja) 2010-07-14
RU2005121669A (ru) 2007-01-20
AU2003289998A1 (en) 2004-06-30
WO2004052932A2 (en) 2004-06-24
SI1572745T1 (sl) 2010-12-31
CA2509068C (en) 2012-02-07
PL377506A1 (pl) 2006-02-06
DK1572745T3 (da) 2010-10-25
GB0228832D0 (en) 2003-01-15
CN100384877C (zh) 2008-04-30
NO20053304L (no) 2005-09-07
US8535666B2 (en) 2013-09-17
ZA200504522B (en) 2006-03-29
CA2509068A1 (en) 2004-06-24
KR101215801B1 (ko) 2012-12-26
PT1572745E (pt) 2010-10-21
ATE475671T1 (de) 2010-08-15
MXPA05006265A (es) 2005-12-05
RU2350623C2 (ru) 2009-03-27
BR0317161A (pt) 2005-11-01
JP2006523087A (ja) 2006-10-12
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29

Similar Documents

Publication Publication Date Title
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
Pisarewicz et al. Polypeptide chains containing d-γ-hydroxyvaline
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700136A1 (ru) Анти-cd154-антитела
DE60224291D1 (de) System zur antikörperexpression und- synthese
CA2256308A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
MX2009013955A (es) Dominios de union de proteina morfogenica osea (bmp) de proteinas de la familia de proteina de molecula repulsiva de la direccion (rgm) y sus fragmentos funcionales, y su uso.
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ&#39;ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
BR0115978A (pt) Cadeia leve, cadeia pesada, imunoglobulina ou fragmento de ligação de antìgeno, anticorpo humanizado ou fragmento de ligação de antìgeno do mesmo, métodos para prevenir ou tratar uma doença amiloidogênica e doença de alzheimer em um paciente, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, mólecula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, ou fragmento do mesmo, método para identificar resìduos que levem à substituição em uma região de esqueleto variável de imunoglobina 3d6 humanizada, uso de seguência de região variável especificada, e, molécula de ácido nucleico isolada
WO2006087637A3 (en) Anti her2/neu antibody
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
BRPI0414174B8 (pt) anticorpos ou fragmentos de ligação a antígeno do mesmo uso dos mesmos, polinucleotídeo, vetor, sistema de expressão, e composição farmacêutica.
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
Liu et al. Effect of the light chain C-terminal serine residue on disulfide bond susceptibility of human immunoglobulin G1λ
ATE401402T1 (de) Mit syndekan interagierende proteine und deren verwendung
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания